Next-Generation Sequencing found to be most cost-effective in metastatic NSCLC


The study investigated the economic impact of NGS compared with other three testing strategies, including sequential, exclusionary, and panel, in patients with metastatic NSCLC. The researches created a decision analytic model to find out which approach was the most cost effective and efficient. The results showed that the estimated time to receive results for NGS and panel was 2 weeks; which was 2.8 and 2.7 times faster than sequential testing and exclusionary testing, respectively. In addition, using CMS reimbursement, NGS resulted in a savings of $1.4 million versus exclusionary testing, $1.5 million versus sequential testing, and more than $2.1 million versus panel testing. This study demonstrated that upfront NGS testing was most cost-effective and should be the standard of care.   

 Source : Pennell NA, Mutebi A, Zhou Z, et al. J Clin Oncol. 2018;36 (suppl; abstr 9031)